Entrada Therapeutics (TRDA) Revenue (2023 - 2026)

Entrada Therapeutics' Revenue history runs 4 years deep, the most recent figure standing at $875000.0 for Q1 2026.

• In Q1 2026, Revenue fell 95.74% year-over-year to $875000.0; the TTM figure through Mar 2026 stood at $5.7 million (down 96.67% YoY), while the FY2025 annual figure was $25.4 million, down 87.94% from the prior year.
• Revenue was $875000.0 for Q1 2026 at Entrada Therapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $94.7 million in Q2 2024 to a low of $875000.0 in Q1 2026.
• Historically, Revenue has averaged $28.2 million across 4 years, with a median of $20.6 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Revenue jumped 421.16% in 2024, then slumped 97.94% in 2025.
• A 4-year view of Revenue shows it stood at $41.8 million in 2023, then dropped by 10.63% to $37.4 million in 2024, then tumbled by 96.53% to $1.3 million in 2025, then slumped by 32.64% to $875000.0 in 2026.
• The last three Revenue figures came in at $875000.0 (Q1 2026), $1.3 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.